Winning the go-to-market game: Standing out in tomorrow’s complex healthcare ecosystems
Ahead of Reuters Pharma 2022, Antonio Iervolino, Partner out of our Putnam London office describes 5 major shifts that pharma companies will have to embrace as they design the path to market for their novel assets and provides an analysis on pharma product launches since 2018, identifying trends and measuring their performance against pre-launch expectations.
Antonio distills the key drivers that are critical in developing a virtuous value creating system and designing impactful go-to-market strategies for tomorrow’s healthcare ecosystems.
Read more on the thoughtful analysis and hear from Antonio at Pharma 2022 next week.
Jump to a slide with the slide dots.
Mariia Dronova
Value of Equity in HTA: Current Guidelines and What to Expect
Equity in HTA is evolving. Explore current guidelines, future trends, and how Putnam advances equity methods in health assessments.
Read more
Thomas Leahy
Why Real-World External Control Arms Are Gaining Ground in Health Technology Assessment
Discover how real-world external control arms (RW-ECAs) provide robust comparative evidence for HTA submissions when RCTs are impractical or unethical
Read more
Yemi Oluboyede
Unlocking Patient Insights in HEOR Through Netnography: A Scalable Qualitative Research Method
In pharma commercialization, AI and analogs set the stage, but human insight drives strategies that break precedent and win markets
Read more